CTOR

Citius Oncology, Inc. NASDAQ Listed Dec 8, 2022

Healthcare ·Drug Manufacturers - General ·US · citiusonc.com/overview/default.aspx

$0.90

Mkt Cap $79.5M

52w Low $0.49 7.2% of range 52w High $6.19

50d MA $0.83 200d MA $1.34

P/E (TTM) -2.8x

EV/EBITDA -6.3x

P/B 1.5x

Debt/Equity 0.1x

ROE -40.5%

P/FCF -27.1x

RSI (14) —

ATR (14) —

Beta 3.43

50d MA $0.83

200d MA $1.34

Avg Volume 260.0K

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

SIC Code

2834

CIK (SEC)

1851484

Phone

347-627-0058

420 Lexington Avenue · New York City, NY 10170 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 13, 2026	AMC	-0.04	-0.06	-50.0%	1.22	+0.0%	-3.3%	-0.8%	+3.4%	-4.1%	-1.7%	—
Dec 23, 2025	AMC	-0.06	-0.06	+0.0%	1.27	-3.1%	-9.4%	-1.7%	-8.8%	+1.9%	-4.8%	—
Aug 12, 2025	AMC	-0.15	-0.08	+46.7%	1.69	+0.6%	+5.9%	-3.9%	-1.7%	+3.6%	-2.9%	—
May 14, 2025	AMC	-0.09	-0.11	-22.2%	0.89	+2.3%	-0.6%	+2.1%	+0.7%	-2.2%	-1.6%	—
Feb 14, 2025	AMC	-0.06	-0.09	-50.0%	1.25	-2.4%	-5.6%	+1.7%	+0.0%	-2.5%	+6.8%	—
Dec 27, 2024	AMC	-0.08	-0.07	+10.4%	1.04	+11.5%	+7.7%	+2.7%	+3.5%	+9.2%	+18.5%	—
Mar 31, 2024	AMC	—	0.01	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	—	-0.05	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	0.00	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	0.07	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	0.07	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Sep 23	Maxim Group	Upgrade	Hold → Buy	—	$1.78	$1.90	+6.7%	+1.7%	+0.0%	+0.6%	+9.9%	+1.5%
May 23	Maxim Group	Downgrade	Buy → Hold	—	$0.91	$0.89	-2.2%	+0.0%	-2.2%	+0.4%	-0.4%	+1.1%
Aug 13	EF Hutton	Maintains	Buy → Buy	—	$40.50	$3.35	-91.7%	-92.1%	-22.8%	-8.9%	-11.1%	-2.0%

Data updated apr 25, 2026 3:46am · Source: massive.com